Figure 3.

Differences in the magnitude of change from baseline to day 5 for ALC, ANC, and platelet count in baricitinib+remdesivir recipients in the high-risk quartile.

The figure shows changes in ALC (left), ANC (middle), and platelet count (right), expressed as a ratio of the value at day 5 to the baseline value, by ACTT risk quartile in the baricitinib + remdesivir treatment group. The center of the ratio change distribution is quantified by the geometric mean of the ratio change with the 95% CI. P values are from t tests on the log-transformed ratio changes. ACTT = Adaptive COVID-19 Treatment Trial; ALC = absolute lymphocyte count; ANC = absolute neutrophil count.